Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccination in old age: Immunological and biogerontological characterization of responders and non-responders
2011-002147-10Phase 4
Key facts
- Status
- Terminated
- Start
- Aug 2011
- Countries
- 1
- Sponsor
- Institute for Biomedical Aging Research
- Modality
- Vaccines & Immunotherapeutics
- Conditions
- influenza
01
Overview
Phase 4, open-label, single-arm trial of influenza a h1n1 whole virus vaccine in influenza, sponsored by Institute for Biomedical Aging Research. Primary endpoint: Quantification of vaccine-induced immune responses at 4 weeks. Started Aug 2011; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Prefluvac vaccination arm
Healthy adults over 35 years receiving single-dose trivalent inactivated influenza vaccine (Prefluvac) with subsequent immune response assessments.
03
Who it enrols
Healthy adults older than 35 years with signed informed consent; participants with acute illness at the time of vaccination are excluded.
04
Endpoints
Primary
Quantification of vaccine-induced immune responses at 4 weeks
Beyond the preview
Go deeper on 2011-002147-10.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002147-10.